Core Insights - Omega Therapeutics is a clinical-stage biotechnology company focused on developing programmable epigenomic mRNA medicines to treat a wide range of diseases, utilizing a novel approach that modulates gene expression without altering native nucleic acid sequences [1][3][8] - The company has a pipeline of therapeutic candidates derived from its OMEGA platform, targeting areas such as oncology, regenerative medicine, and multigenic diseases, including inflammatory and cardiometabolic conditions [1][3] Company Developments - Richard N. Kender has been elected to the Board of Directors, bringing extensive experience in corporate finance and business development from his 35-year career at Merck & Co., Inc., where he held various roles including Senior Vice President of Business Development [3][5][8] - The leadership team at Omega Therapeutics is described as seasoned and accomplished, with a strong track record of innovation and operational excellence, which is expected to support the company's ambitious vision [1][4][8] Strategic Focus - The company aims to revolutionize genomic medicine through its innovative OMEGA platform, which is designed to enable precision epigenomic control of nearly all human genes, including those that have been historically difficult to target [1][3] - Omega Therapeutics is committed to capitalizing on the vast potential of its platform and advancing its pipeline of novel epigenomic controllers, with strategic insights from its newly appointed board member expected to play a crucial role [8]

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences. Jefferies Global Healthcare Conference About Omega Therapeutics Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmabl ...

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences. Jefferies Global Healthcare Conference Date: Thursday, June 6, 2024 Time: 9:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 10:40 ...

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. "Kaan is an accomplished bio ...

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the appointment of Kaan Certel, Ph.D., as Chief Business Officer. Dr. Certel brings to Omega extensive biopharmaceutical industry experience and will be responsible for global business development activities including strategic partnerships. "Kaan is an accomplished bio ...

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.26%. A quarter ago, it was expected that this company would post a loss of $0.46 per share when it actually produced a loss of $0.37, delivering a surprise of 19.57%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2024 OR WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-40657 Omega Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 6, 2024 (GLOBE NEWSWIRE) – Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress. "Our consistent focus on execution in the past quarter led to mean ...

Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data demonstrating potential of a MYC-targeting epigenomic controller in NSCLC at AACR 2024Company to present new preclinical data demonstrating durable epigenomic upregulation and other OMEGA platform capabilities at ASGCT 2024 CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40657 Omega Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-3247585 (State or other jurisdictio ...